Biotwitter is awash with tweets at the moment saying how weak US small cap biotechs are right now - there apparently is just no buying demand at all and price are falling on very small volume (sounds familiar).
I would say you are right that the chance of a partnership being announced as part of the strategic update is very low. What I am hoping for is a detailed clinical program with costs and timelines outlined and the reasons for these changes. I would also love to see what other alternatives were considered.
General Comments / Chat, page-8608
-
- There are more pages in this discussion • 2,660 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add RAC (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$1.44 |
Change
0.040(2.86%) |
Mkt cap ! $245.3M | |||
| Open | High | Low | Value | Volume |
| $1.45 | $1.49 | $1.41 | $101.7K | 69.88K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 9216 | $1.44 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.47 | 7767 | 2 |
View Market Depth
| Last trade - 16.10pm 09/08/2024 (20 minute delay) ? |
| RAC (ASX) Chart |